Topic: bladder cancer

BioClin raises $30M Series B round for bladder cancer candidate

Quiet upstart BioClin Therapeutics has raised $30 million in a Series B funding round, taking its total to $59 million since its founding, as it aims to push on with clinical work on its bladder cancer candidate B-701 that includes a combo test with Roche’s new PD-L1 med.